Etudes cliniques en cours

Découvrez ici la liste des différentes études cliniques en cours classées par centre.

CHU Liège

  • Neodjuvant/adjuvant
    NSCLC resectable Iib/IIIa
    MK3475-671
    Platinum doublet chemotherapy ± pembrolizumab
  • 1-2LM
    NSCLC Squameux/non-squameux
    CANFOUR
    • Cisplatine/gemcytabine + CAN 04
    • CAN04 seul
  • NSCLC
    Slots variables
    GCT1021 -01
    Humax-AXL-ADC
  • NSCLC
    Slots variables
    CNIR
    PDR001 + NIR178
  • adjuvant
    NSCLC RO
    GO39733
    Atezolizumab + vaccin personnalisé
  • NSCLC
    Slots variables
    Pivot 02
    Nektar-IL2 + nivo Q3W

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

  • PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
  • Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

  • BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

  • ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

Etudes Onco en cours
1st line
AcronymeStudiesCancerPI
BO29554 study (B-FAST)A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)NSCLC (ROS+) A venir: BRAF V600+P.C
ADRIATIC (D933QC00001)Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)SCLC limités post-chimioradioT.P
ANAM 17-21A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLCNSCLC cachexiaT.P
Zenith20 (Spectrum) (SPI-POZ-202)Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)NSCLC IV EGFR ou HER2 exon 20 inser/mutT.P
CA209-73LA Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)NSCLC IIIA/B/CTP
2nd line
ImmunoSABRPhase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer NSCLC IVX.G
AMG510 (20190009)A Phase 3 Multicenter, Randomized, Open
Label, Active-controlled, Study of AMG 510
Versus Docetaxel for the Treatment of Previously
Treated Locally Advanced and Unresectable or
Metastatic NSCLC Subjects With Mutated KRAS
p.G12C
NSCLC KRAS p.G12CThP
3rd line
ImmunoSABRPhase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer NSCLC IVX.G
Autres
AcronymeStudiesCancerPI
EORTC: E2-Radiate 1811E²-RADIatE:
EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
Tous cancers oligométa traités par RthXG
PACIFIC R D4194R00005First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapyNSCLC stage III with durvalumab post chimioradioT.P
Immuno PoumonEtude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumonNSCLC FAb
SPECTAScreening Cancer Patients for Efficient Clinical Trial AccessNSCLC IV naïfs/ thymomes, mésothéliome IV naïfsT.P

GHdC

Pathologie-catégoriePathologieNomCodeEudractTitreMoleculesPhaseEtude
Poumons et ThoraxNSCLC/SCLC0115101151Cardiovascular morbidities and lung cancer treatment: a prospective registryObservationnelle
Poumons et ThoraxNSCLCPDC-Lung-101PDC-Lung-1012018-002382-19An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) PDC*lung01Phase 1
Phase 2
Poumons et ThoraxNSCLCANAM-17-21ANAM-17-212018-002927-40A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated
weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
Anamorelin HCLPhase 3
Poumons et ThoraxNSCLCPACIFIC-4D9103C000012018-002572-41A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)DurvalumabPhase 3
Poumons et ThoraxNSCLCCodeBreak 20020190009 2019‐003582‐18A phase 3 multicenter, randomized, open label, active-controlled, study of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with KRAS p.G12C mutationAMG 510Phase 3
Poumons et ThoraxNSCLCEXCLAIM-2
(On hold - futility analysis)
TAK-788-30012019-001845-42Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
TAK-788 Phase 3
Poumons et ThoraxNSCLCSkyscraper 03GO418542019-0044773-29A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation.TiragolumabPhase 3
Poumons et ThoraxNSCLCMARIPOSA73841937NSC30032020-000743-31A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer – MARIPOSAJNJ-61186372 AmivantamabPhase 3
Poumons et ThoraxNSCLCSAPPHIRE516-0052019-001043-41 A randomized phase 3 study of Sitravatinib in combination with Nivolumab versus Docetaxel in patients with advanced non-squamous non-small cell lung cancer with disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.SitravatinibPhase 3
Poumons et ThoraxSCLCMK7339-013 MK7339-013 2019-003616-31A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) Pembrolizumab (MK-3475)Phase 3
Toutes TumeursToutes tumeursTumorbaseONCOGHDC2017-01Prospective collection of biological samples for translational research on patients with tumoral or hematological diseases (TUMOR-base)Prospective-
Collection d'échantillons
Toutes TumeursToutes tumeursPrecision 2 - Afatinib1200.2642016-003411-34 Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression.AfatinibPhase 2
Toutes TumeursToutes tumeursDRIIV-1 / Phase Ib comboOX2016-203-01 2017-000088-34Etude de Phase I/Ib d’escalade de dose en ouvert destinée à évaluer la tolérance,la pharmacocinétique et la pharmacodynamique d’AsiDNATM, un inhibiteur de réparation de l’ADN administré par voie intraveineuse en monothérapie et à évaluer la tolérance et l'efficacité d'AsiDNA administré en association avec Carboplatine avec ou sans Paclitaxel chez des patients atteints de tumeurs solides à un stade avancé. AsiDNATMPhase 1
Phase 1b
Toutes TumeursToutes tumeursPrecision 2 – Olaparib 1-2018 BSMO2018-002966-37 Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene
Olaparib Phase 2
Toutes TumeursToutes tumeursRAGNAR42756493CAN20022019-002113-19A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene AlterationsErdafitinibPhase 2
Prospective-
Collection d'échantillons
Toutes TumeursToutes tumeursPrecision 1 BSMO 2014-2The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment
“PRECISION 1”
Prospective-
Collection d'échantillons
Toutes TumeursToutes tumeursGeNeoBSMO 2020-01A study to examine the value of broad agnostic NGS panel testing versus reimbursed organ-directed NGS: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre.
Prospective-
Collection d'échantillons
Toutes TumeursToutes tumeursTAPISTRYBO419322020-001847-16Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assayPhase 2

Login

Connectez-vous pour avoir accès au contenu privé.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Ok